AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults June 2, 2026 mental-health ONLY AVAILABLE IN PAID PLANS. Originally reported by cision. Read more Source: https://www.prnewswire.com/news-releases/abbvie-announces-european-commission-approval-of-aquipta-atogepant-for-the-acute-treatment-of-migraine-in-adults-302787637.html
